Brodalumab
- Generic Name
- Brodalumab
- Brand Names
- Siliq, Kyntheum
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1174395-19-7
- Unique Ingredient Identifier
- 6ZA31Y954Z
- Background
Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
- Indication
Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.
- Associated Conditions
- Severe Plaque psoriasis, Moderate Plaque psoriasis
- Associated Therapies
- -
Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2019-07-10
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT03478280
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 39
- Registration Number
- NCT03403036
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Molecular Signatures in Inflammatory Skin Disease
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Prof. Dr. Stephan Weidinger
- Target Recruit Count
- 300
- Registration Number
- NCT03358693
- Locations
- 🇩🇪
Department of Dermatology, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 159
- Registration Number
- NCT02985983
- Locations
- 🇯🇵
Tenri Hospital, Nara, Japan
🇯🇵Fukuoka University Hospital, Fukuoka, Japan
🇯🇵Kyusyu University Hospital, Fukuoka, Japan
A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 145
- Registration Number
- NCT02173392
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01937260
- Locations
- 🇳🇿
Research Site, Grafton, Auckland, New Zealand
Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2021-12-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 252
- Registration Number
- NCT00950989
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.